Integrating genomics and proteomics-oriented biomarkers to comprehend lung cancer

Bibliography

• Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350(4):379-92
   PubMed Web of Science ®Google Scholar
• Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005;32(3):169-76
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5(10):588-99
   PubMedGoogle Scholar
• Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1(4):304-13
   PubMed Web of Science ®Google Scholar
• Reymond MABM, Lippert H. Proteomics in Lung Cancer. In: DAOUD SS, editor, Cancer Proteomics: from bench to bedside. Totowa, New Jersy: Humana Press, 2008. p. 139-59
   Google Scholar
• Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356(1):11-20
   PubMed Web of Science ®Google Scholar
• Bignell GR, Huang J, Greshock J, et al. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 2004;14(2):287-95
   PubMed Web of Science ®Google Scholar
• Greshock J, Feng B, Nogueira C, et al. A comparison of DNA copy number profiling platforms. Cancer Res 2007;67(21):10173-80
   PubMed Web of Science ®Google Scholar
• Anderson JE, Hansen LL, Mooren FC, et al. Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicine. Drug Resist Updat 2006;9(4-5):198-210
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98(24):13790-5
   PubMed Web of Science ®Google Scholar
• Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8(8):816-24
   PubMed Web of Science ®Google Scholar
• Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62(11):3005-8
   PubMed Web of Science ®Google Scholar
• Natsume T, Nakamura T, Koh Y, et al. Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes. Invest New Drugs 2001;19(4):293-302
   PubMed Web of Science ®Google Scholar
• Ohira T, Akutagawa S, Usuda J, et al. Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray. Oncol Rep 2002;9(4):723-8
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22(14):2192-205
   PubMed Web of Science ®Google Scholar
• Iwao K, Watanabe T, Fujiwara Y, et al. Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Int J Cancer 2001;91(4):433-7
   PubMed Web of Science ®Google Scholar
• Hibi K, Liu Q, Beaudry GA, et al. Serial analysis of gene expression in non-small cell lung cancer. Cancer Res 1998;58(24):5690-4
   PubMed Web of Science ®Google Scholar
• Dan S, Tsunoda T, Kitahara O, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002;62(4):1139-47
   PubMed Web of Science ®Google Scholar
• Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001;98(19):10787-92
   PubMed Web of Science ®Google Scholar
• Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008;26(6):877-83
   PubMed Web of Science ®Google Scholar
• Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66(15):7466-72
   PubMed Web of Science ®Google Scholar
• Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355(6):570-80
   PubMed Web of Science ®Google Scholar
• Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25(35):5562-9
   PubMed Web of Science ®Google Scholar
• Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008;14(15):4794-9
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455(7216):1069-75
   PubMed Web of Science ®Google Scholar
• Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62(21):6240-5
   PubMed Web of Science ®Google Scholar
• Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002;99(20):12963-8
   PubMed Web of Science ®Google Scholar
• Sweet-Cordero A, Tseng GC, You H, et al. Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 2006;45(4):338-48
   PubMed Web of Science ®Google Scholar
• Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196(1):1-7
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95(20):11891-6
   PubMed Web of Science ®Google Scholar
• Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001;61(11):4556-60
   PubMed Web of Science ®Google Scholar
• Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1(1):61-7
   PubMed Web of Science ®Google Scholar
• Machida EO, Brock MV, Hooker CM, et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006;66(12):6210-8
   PubMed Web of Science ®Google Scholar
• Brock MV, Kim MP, Hooker CM, et al. Pulmonary resection in octogenarians with stage I nonsmall cell lung cancer: a 22-year experience. Ann Thorac Surg 2004;77(1):271-7
   PubMed Web of Science ®Google Scholar
• Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101(32):11755-60
   PubMed Web of Science ®Google Scholar
• Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 2004;101(26):9740-4
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Jiang J, Liu Q, et al. A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res 2004;32(4):e43
   PubMed Web of Science ®Google Scholar
• Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65(21):9628-32
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9(3):189-98
   PubMed Web of Science ®Google Scholar
• Wu X, Xiao Z, Chen Z, et al. Differential analysis of two-dimension gel electrophoresis profiles from the normal-metaplasia-dysplasia-carcinoma tissue of human bronchial epithelium. Pathol Int 2004;54(10):765-73
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Y, Chen Y, et al. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer 2007;57(1):37-45
   PubMed Web of Science ®Google Scholar
• Zhukov TA, Johanson RA, Cantor AB, et al. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003;40(3):267-79
   PubMed Web of Science ®Google Scholar
• Chen G, Wang H, Gharib TG, et al. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2003;2(2):107-16
   PubMed Web of Science ®Google Scholar
• Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362(9382):433-9
   PubMed Web of Science ®Google Scholar
• Seike M, Kondo T, Fujii K, et al. Proteomic signatures for histological types of lung cancer. Proteomics 2005;5(11):2939-48
   PubMed Web of Science ®Google Scholar
• Jain KK. Biomarkers: Technologies, companies and markets, Basel, Switzerland; 2007. p. 1-620
   Google Scholar
• Au JS, Cho WC, Yip TT, et al. Deep proteome profiling of sera from never-smoked lung cancer patients. Biomed Pharmacother 2007;61(9):570-7
   PubMed Web of Science ®Google Scholar
• Cleveland clinic recognizes Circulating Tumor cell technology as top medical innovation for 2009 (Last visited: Jan 2009). Available from: http://www.medicalnewstoday.com/articles/129501.php
   Google Scholar
• Nielsen J, Oliver S. The next wave in metabolome analysis. Trends Biotechnol 2005;23(11):544-6
   PubMed Web of Science ®Google Scholar
• Celis JE, Moreira JM, Gromova I, et al. Towards discovery-driven translational research in breast cancer. Febs J 2005;272(1):2-15
   PubMed Web of Science ®Google Scholar
• Zhang X, Li L, Wei D, et al. Moving cancer diagnostics from bench to bedside. Trends Biotechnol 2007;25(4):166-73
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62(15):4427-33
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004;101(25):9309-14
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet 2005;37(Suppl):S31-7
   Web of Science ®Google Scholar
• Elkon R, Linhart C, Sharan R, et al. Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res 2003;13(5):773-80
   PubMed Web of Science ®Google Scholar
• Cancer Biomedical Informatics grid, Community website to connect entire cancer community (Last visited: Jan 2009). Available from: http://cabig.nci.nih.gov
   Google Scholar
• Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003;49(5):752-60
   PubMed Web of Science ®Google Scholar
• McConnell P, Dash RC, Chilukuri R, et al. The Cancer Translational Research Informatics Platform. BMC Med Inform Decis Mak 2008;8(1):60
   PubMedGoogle Scholar
• Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452(7187):571-9
   PubMed Web of Science ®Google Scholar
• Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89(18):1366-73
   PubMed Web of Science ®Google Scholar
• Jakupciak JP, Dakubo GD, Maragh S, et al. Analysis of potential cancer biomarkers in mitochondrial DNA. Curr Opin Mol Ther 2006;8(6):500-6
   PubMed Web of Science ®Google Scholar
• Verma M, Kumar D. Application of mitochondrial genome information in cancer epidemiology. Clin Chim Acta 2007;383(1-2):41-50
   PubMed Web of Science ®Google Scholar
• Sueoka E, Sueoka N, Goto Y, et al. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res 2001;61(5):1896-902
   PubMed Web of Science ®Google Scholar
• Tominaga M, Sueoka N, Irie K, et al. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer 2003;40(1):45-53
   PubMed Web of Science ®Google Scholar
• Gharib TG, Chen G, Wang H, et al. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 2002;4(5):440-8
   PubMed Web of Science ®Google Scholar
• Fujii K, Nakano T, Kanazawa M, et al. Clinical-scale high-throughput human plasma proteome analysis: lung adenocarcinoma. Proteomics 2005;5(4):1150-9
   PubMed Web of Science ®Google Scholar
• Okuzawa K, Franzen B, Lindholm J, et al. Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1994;15(3-4):382-90
   PubMed Web of Science ®Google Scholar
• Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003;41(2):155-62
   PubMed Web of Science ®Google Scholar
• Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003;88(8):1229-33
   PubMed Web of Science ®Google Scholar
• Ueno T, Linder S, Na CL, et al. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem 2004;279(16):16178-84
   PubMed Web of Science ®Google Scholar
• Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 2003;100(23):13537-42
   PubMed Web of Science ®Google Scholar
• Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008;41(9):615-25
   PubMed Web of Science ®Google Scholar
• Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 2008;23(Suppl):178-84
   Google Scholar
• Chi-Shing Cho W. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 2007;61(9):515-9
   PubMed Web of Science ®Google Scholar
• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12(8):895-904
   PubMed Web of Science ®Google Scholar
• Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450(7173):1235-9
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359(4):366-77
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120(5):635-47
   PubMed Web of Science ®Google Scholar
• Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21(9):1025-30
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008;7(6):759-64
   PubMed Web of Science ®Google Scholar
• Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17(15):1298-307
   PubMed Web of Science ®Google Scholar
• Hurteau GJ, Carlson JA, Spivack SD, et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007;67(17):7972-6
   PubMed Web of Science ®Google Scholar
• Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104(40):15805-10
   PubMed Web of Science ®Google Scholar
• Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008;27(27):3845-55
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Bemis LT, Nakajima E, et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008;19(6):1053-9
   PubMed Web of Science ®Google Scholar
• Haab BB. Methods and applications of antibody microarrays in cancer research. Proteomics 2003;3(11):2116-22
   PubMed Web of Science ®Google Scholar
• Jain KK. Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics 2004;1(1):49-55
   PubMed Web of Science ®Google Scholar
• Jain KK. Using proteomics to identify targets and validate leads. Trends Biotechnol 2002;20(8):319-20
   PubMedGoogle Scholar
• Holdenrieder S, Stieber P, Von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10(18 Pt 1):5981-7
   PubMed Web of Science ®Google Scholar
• Chan-Hui PY, Stephens K, Warnock RA, et al. Applications of eTag trade mark assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin Immunol 2004;111(2):162-74
   PubMed Web of Science ®Google Scholar
• Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274(5289):998-1001
   PubMed Web of Science ®Google Scholar
• Wiesner A. Detection of tumor markers with ProteinChip technology. Curr Pharm Biotechnol 2004;5(1):45-67
   PubMed Web of Science ®Google Scholar
• Han KQ, Huang G, Gao CF, et al. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 2008;31(2):133-9
   PubMed Web of Science ®Google Scholar
• Molina R, Filella X, Auge JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;24(4):209-18
   PubMed Web of Science ®Google Scholar
• Barlesi F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 2004;98(4):357-62
   PubMed Web of Science ®Google Scholar
• Reinmuth N, Brandt B, Semik M, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002;36(3):265-70
   PubMed Web of Science ®Google Scholar
• Barak V, Goike H, Panaretakis KW, et al. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37(7):529-40
   PubMed Web of Science ®Google Scholar
• Molina R, Filella X, Auge JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004;37(7):505-11
   PubMed Web of Science ®Google Scholar
• Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001;32(1):61-9
   PubMed Web of Science ®Google Scholar
• Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006;42:1-41
   PubMed Web of Science ®Google Scholar